ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 103

Unexpectedly High Incidence of Kawasaki Disease in a Well-Characterized Population in Atlantic Canada

Abdulrahman Alkanhal1, Joseph , Saunders 2, Fajer Altammar 3, Adam Huber 4, Andrew Lynk 2, Alison MacLeod 5, Oliva Ortiz-Alvarez 6, Meighan Adams 2, Suzanne Ramsey 7, Elizabeth Stringer 7, Andrew Warren 2 and Bianca Lang 8, 1University of Alberta, Edmonton, Alberta, Canada, 2Dalhousie University, Halifax, Canada, 3Mcmaster University, Hamilton, Canada, 4IWK Health Centre & Dalhousie University, Halifax, Nova Scotia, Canada, 5Annapolis Valley Health, Kentville, Canada, 6St Martha's Regional Hospital, Antigonish, Canada, 7IWK Health Centre, Halifax, Canada, 8Dalhousie University - Halifax, Halifax, Canada

Meeting: 2020 Pediatric Rheumatology Symposium

Keywords: coronary artery disease, Epidemiologic methods, Kawasaki disease

  • Tweet
  • Email
  • Print
Session Information

The 2020 Pediatric Rheumatology Symposium, originally scheduled for April 29 – May 2, was postponed due to COVID-19; therefore, abstracts were not presented as scheduled.

Date: Friday, May 1, 2020

Title: Poster Session 2

Session Type: ACR Abstract Session

Session Time: 5:00PM-6:00PM

Background/Purpose: Kawasaki Disease (KD), a systemic vasculitis of unknown etiology, is now the leading cause of acquired heart disease in children in North America. Its reported incidence varies widely around the world. A recent pan-Canadian study utilizing hospital discharge data reported an unexpectedly high incidence of KD in Atlantic Canada. The primary goal of this study was to validate the finding of a high incidence of KD in an Atlantic Canadian province and review factors contributing to the frequency in our population.

Methods: Our study was a retrospective review of all patients less than 16 years of age from the province of Nova Scotia (NS) diagnosed with KD between July 2007 and June 2018. All children with KD in NS undergo echocardiography evaluated in one central location. We used the cardiology and discharge databases of the pediatric tertiary care center, and the provincial Medical Examiner database to identify patients with KD. Clinical information was collected by health record review using a standardized form following local ethics approval. The 2011 Canadian census population data were used to calculate incidence rates and determine the proportion of the population of Asian descent.

Results: Out of the 309 possible KD cases that we identified, 220 residents of the province were diagnosed with KD during the study period. Exclusions are shown in Figure 1. Patients were included if they were treated for KD with IVIG (87%) or, if untreated, the physician diagnosed KD and obtained echo follow-up (13%). Cases where the physician subsequently doubted the diagnosis of KD were recorded. The annual incidence was 29.6, 13.9 and 1.6 per 100,000 children < 5 years, 5 to less than 10 years and 10 to less than 15 years, respectively (recurrence rate 1.8%). The male to female ratio was 1.3:1; the median age was 3.6 years (range 18 days-14.6 years). 61.4% and 23.2% met American Heart Association criteria for complete and incomplete KD, respectively. All patients diagnosed in the acute phase received IVIG; 12% of patients were refractory to the initial IVIG dose; 8% of treated patients received steroid and or biologic therapy. 14 (6%) developed a coronary artery aneurysm (CAA) during the disease course. One death from cardiac arrest occurred in a child with a large CAA with thrombosis. The proportion of our population of Asian descent was 1.25%.

Conclusion: We have confirmed a high incidence of KD in the specified Atlantic province. Other features of KD (age, sex, recurrence rate, IVIG resistance and CAA) are similar to previous studies. The incidence is higher than that reported in Europe and the United States (4.5-15 and 19 per 100,000 children < 5 years, respectively), similar to Canadian provinces with significantly higher proportions of the population of Asian descent (20-26 per 100,000 children < 5 years), and among the highest reported outside of Asia. Local population ethnicity does not explain our findings. Our comprehensive method to capture KD patients may have contributed to the detection of the higher than expected incidence, raising the possibility that the incidence of KD has been underestimated in other populations. The role of environmental and genetic factors also deserves further study


Disclosure: A. Alkanhal, None; J. Saunders, None; F. Altammar, None; A. Huber, None; A. Lynk, None; A. MacLeod, None; O. Ortiz-Alvarez, None; M. Adams, None; S. Ramsey, None; E. Stringer, None; A. Warren, None; B. Lang, None.

To cite this abstract in AMA style:

Alkanhal A, Saunders J, Altammar F, Huber A, Lynk A, MacLeod A, Ortiz-Alvarez O, Adams M, Ramsey S, Stringer E, Warren A, Lang B. Unexpectedly High Incidence of Kawasaki Disease in a Well-Characterized Population in Atlantic Canada [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 4). https://acrabstracts.org/abstract/unexpectedly-high-incidence-of-kawasaki-disease-in-a-well-characterized-population-in-atlantic-canada/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2020 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/unexpectedly-high-incidence-of-kawasaki-disease-in-a-well-characterized-population-in-atlantic-canada/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology